Ayesha Butt, MD
@AyeshaButtMD
Resident Physician @YaleIMed⬅️Postdoctoral Research Associate, Hematology @YaleCancer | CFN Leadership Council Member @HTRStoday |Views my own #HemeOncMatch2025
Excited to share our paper in @JCOOP_ASCO about bias against IMGs and DEI themes in fellowship recruitment. This one's very close to my heart as I am an IMG myself ascopubs.org/doi/full/10.12… Thank u to all who have reached out to me to share how much you resonated with this paper
From AKU Pakistan 🇵🇰 to global impact 🌍—Proud to see #AKUAlumnus Dr Adnan Hyder (MD ’90 @AKU_Pakistan) named Dean of Boston U’s School of Public Health. A leader in global health, injury prevention & equity—congratulations on this remarkable milestone! #BUpublichealth
Congratulations @tariqkewan !! So excited for your journey @MayoClinic Thank you for all the teaching and support!!
Many congratulations to our outstanding past fellow @tariqkewan as he graduates from @YaleCancer @YaleHemOnc @YaleHematology @Yale and moves on to the highly prestigious @MayoClinic as a myeloid cancer expert. Look forward to seeing Tariq’s continued rise in the field
Surreal to finally be applying this cycle for hematology oncology fellowship, with a focus on classical heme- it’s been a dream that started as a med student & has only strengthened as I made my way through a postdoc in classical heme @YaleCancer and then residency @TradIMYale…
Big sis @NazliDizman presented an innovative trial evaluating the first bispecific PDL1/VEGF targeting agent Always one step ahead! Looking forward to seeing results! @OncoAlert
Hi again! 👋🏻 My name is Juan, I’m a PGY-3 at Yale applying to cardiology. Interested in HF, global health, and med ed. Excited to connect with future colleagues and mentors! #CardiologyFellowship 🫀 @TradIMYale @YaleIMed @MarkDSiegel1 @YaleCardiology
Thanks to @OncBrothers for the invitation to discuss non-metastatic NSCLC! The field is complex- but the rules are clear: 1) mandatory upfront NGS, 2) comprehensive radiographic and nodal staging, 3) multiD eval and shared decision making will lead us to deliver best care. #LCSM
Treatment Algorithm: This is the algorithm we have used during our discussion w/ @DeepaRangachari for Stage I-III non-small cell #LungCancer #OncTwitter #MedTwitter #lcsm
A heartfelt welcome to these 7 brilliant, kind @BIDMC_HOFellows who will no doubt drive our field forward with their curiosity, compassion, and grit! @rushadpatell @BIDMC_CancerCtr
✨Grateful to be part of this incredible team and to work alongside patients and advocates who give true meaning to our work @DrChoueiri @BraunMDPhD @kidneycan
1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? @Cancer_Cell What drives exceptional response with immunotherapies?…
Honored to be part of this!! Congratulations on this important work @royaryam @DrChoueiri @NazliDizman @NazliDizman et al
🚨Proud to share our publication in @JCOOP_ASCO 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! @DrChoueiri @NazliDizman @ZiadBakouny @IMG_Oncologists @GlopesMd
🚨Proud to share our publication in @JCOOP_ASCO 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! @DrChoueiri @NazliDizman @ZiadBakouny @IMG_Oncologists @GlopesMd
Another important emerging area extensively discussed at #ISTH2025 was immune-thrombotic mechanisms and several talks reported how inflammation and thrombosis interplay in #complex diseases leading to #microvascular disorders. This is a future of Medicine
The first year fellows are almost here, and we are so thrilled. Welcome! We were feeling incomplete without you. And congratulations to our senior fellows on finishing the year strong. The future of hematology and oncology is oh so bright! ✨️
Welcome to an outstanding group of heme/onc fellows joining @YaleCancer @YaleMed @YaleHematology @YaleHemOnc & a special welcome to dr Razan Mansour who is the first 🇯🇴 female fellow to join the combined Heme/Onc fellowship at @Yale following footsteps of @tariqkewan the first 🇯🇴…
The reduced their maternal mortality by HALF! But still 20-100x rate in resource rich areas. 💔 thinking about how many lives could be saved with just some funding.
Absolutely incredible results from large >16k #women prospective study improving maternal morbidity & mortality through proactive interventions to prevent PPH #ISTH2025
So proud of you @SamPNovotny !! Check out her phenomenal work ⬇️
Excited to share our latest study offering insights into genetic variants of uncertain significance in patients being evaluated for inborn errors of immunity🧬 @YaleRheumAller1 @TradIMYale sciencedirect.com/science/articl…
Wow, @SamPNovotny! Fantastic work! @TradIMYale @YaleIMed
Excited to share our latest study offering insights into genetic variants of uncertain significance in patients being evaluated for inborn errors of immunity🧬 @YaleRheumAller1 @TradIMYale sciencedirect.com/science/articl…
#RivaGate in DC at @isth 2025 In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE. 🙏🙏🙏 @LanaCastellucci for this arguably most important DOAC study ever @bbikdeli @isabellemahe1 @LaurentBertole1
Meta-analysis on GLP-1RA (vs. placebo) and VTE: 🔹 PE rates significantly lower 📉 🔹 VTE rates lower but not statistically significant 🔹 No difference in DVT 🔹 Study design matters: RCTs vs. observational data Accepted for publication in JTH! #ISTH2025 #VTE #GLP1RA #Thrombosis
🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️…